Meta-analysis on novel biomarker use in lung cancer screening

Lung cancer is primarily a leading cause of mortality worldwide. Low dose CT screening promises early diagnosis of lung cancer in a defined high-risk population. where as limited, a complement screening tools as biomarker will enhance the benefit. Biomarkers from a various sampling site: blood, sputum, respiratory epithelium, and other liquid- biopsy were introduced recently. In this comparative meta-analysis review of cohort study and validated clinical trial we present up to date the relevant use of a new biomarker by analyzing, comparing, weighting cost effectiveness and clinical utility. Biomarker development improve the efficiency of a precocious detection of cancer and thereby improve a prognosis. The utilization of DNA-based biomarkers needs refinement trial for validation. While c-miRNA signatures for early tumor’s detection despite technical limitation. Protein-based biomarkers in combination with low dose CT screening was found valuable in evaluation of indeterminate lung nodule. Immune serum conversion, circulating tumor cells, and exhaled breath analyze have offered accuracy with a limitation in sensitivity and specificity. Unbiased, predictive, available and optimal use of molecular biomarker can achieve significant survive in lung cancer.